This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) Beats Q2 Earnings Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of +15.38% and -1.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -466.67% and 2.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -83.33% and 1.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
by Zacks Equity Research
The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent meningococcal vaccination schedule.
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
by Zacks Equity Research
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
by Zacks Equity Research
Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
by Zacks Equity Research
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
by Zacks Equity Research
Phio Pharmaceuticals stock rallies as safety committee gives green light to advance skin cancer candidate to next dose concentration in phase I study.
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up
by Zacks Equity Research
Anixa Biosciences stock jumps 13% on new patent grant for its breast cancer vaccine technology in the United States.
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
by Zacks Equity Research
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
by Zacks Equity Research
Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
by Zacks Equity Research
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
by Zacks Equity Research
The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label in lung cancer.
Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study
by Zacks Equity Research
BAYRY subsidiary Vividion Therapeutics doses the first patient in a phase I study on VVD-159642 to treat advanced solid tumors.
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
by Zacks Equity Research
The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
by Zacks Equity Research
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
by Zacks Equity Research
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
by Zacks Equity Research
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol
by Zacks Equity Research
Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
by Zacks Equity Research
Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
by Zacks Equity Research
The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
by Zacks Equity Research
The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.